Immune rejection: the immune biology of allogeneic hematopoietic stem cell transplantation (from mice to humans) - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 118

[106] Gur H, Krauthgamer R, Bachar-Lustig E, Katchman H, Arbel-Goren R, Berrebi A, et al.
Immune regulatory activity of CD34 + progenitor cells: evidence for a deletion-based
mechanism mediated by TNF-alpha. Blood 2005;105:2585-93.
[107] Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, et al. Effects of
in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:
664-72.
[108] Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K, et al. Graft rejec-
tion following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J
Haematol 1986;63:221-30.
[109] Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, et al. Cyclosporin A and
methotrexate in canine marrow transplantation: engraftment, graft-versus-host dis-
ease, and induction of intolerance. Transplantation 1982;34:30-5.
[110] Storb R, Epstein RB, Thomas ED. Marrow repopulating ability of peripheral blood cells
compared to thoracic duct cells. Blood 1968;32:662-7.
[111] Muller AM, Linderman JA, Florek M, Miklos D, Shizuru JA. Allogeneic T cells impair
engraftment and hematopoiesis after stem cell transplantation. Proc Natl Acad Sci USA
2010;107:14721-6.
[112] Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential
implications for marrow transplantation in humans. J Exp Med 1993;178:703-12.
[113] Martin PJ, Akatsuka Y, Hahne M, Sale G. Involvement of donor T-cell cytotoxic effec-
tor mechanisms in preventing allogeneic marrow graft rejection. Blood 1998;92:
2177-81.
[114] Jiang Z, Adams GB, Hanash AM, Scadden DT, Levy RB. The contribution of cytotoxic
and noncytotoxic function by donor T-cells that support engraftment after allogeneic
bone marrow transplantation. Biol Blood Marrow Transplant 2002;8:588-96.
[115] Panse JP, Bastianelli C, Santos EB, Schwarzinger I, Raff RF, Storb R, et al. Dog leukocyte
antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by
CD4 and CD8 T cells. Transplantation 2003;76:474-80.
[116] Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH. Co-stimulated/Tc2 cells abrogate
murine marrow graft rejection. Biol Blood Marrow Transplant 2004;10:604-13.
[117] Mariotti J, Taylor J, Massey PR, Ryan K, Foley J, Buxhoeveden N, et al. The pento-
statin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell
functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow
Transplant 2011;17:620-31.
[118] Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, et al. Ex vivo rapamycin
generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoi-
etic stem cell graft rejection. J Immunol 2008;180:89-105.
[119] Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, et al. Graft rejec-
tion as a Th1-type process amenable to regulation by donor Th2-type cells through an
interleukin-4/STAT6 pathway. Blood 2008;112:4765-75.
[120] Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW, et al. A phase
I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from
donor marrow for HLA-mismatched unrelated recipients. Blood 1999;94:2192-9.
[121] Miller RG. An immunological suppressor cell inactivating cytotoxic T-lymphocyte pre-
cursor cells recognizing it. Nature 1980;287:544-6.
[122] Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol 1988;6:115-37.
[123] Lapidot T, Lubin I, Terenzi A, Faktorowich Y, Erlich P, Reisner Y. Enhancement of bone
marrow allografts from nude mice into mismatched recipients by T cells void of graft-
versus-host activity. Proc Natl Acad Sci USA 1990;87:4595-9.
[124] Martin PJ. Prevention of allogeneic marrow graft rejection by donor T cells that do
not recognize recipient alloantigens: potential role of a veto mechanism. Blood
1996;88:962-9.
[125] Fowler DH, Whitfield B, Livingston M, Chrobak P, Gress RE. Non-host-reactive
donor CD8 + T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood
1998;91:4045-50.
[126] Reich-Zeliger S, Bachar-Lustig E, Bar-Ilan A, Reisner Y. Tolerance induction in pre-
sensitized bone marrow recipients by veto CTLs: effective deletion of host anti-donor
memory effector cells. J Immunol 2007;179:6389-94.
[127] Ophir E, Eidelstein Y, Afik R, Bachar-Lustig E, Reisner Y. Induction of tolerance to bone
marrow allografts by donor-derived host nonreactive ex vivo-induced central memory
CD8 T cells. Blood 2010;115:2095-104.
[128] Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell recep-
tor and the alpha 3 domain of class I MHC. Science 1991;252:1424-7.
[129] Reich-Zeliger S, Eidelstein Y, Hagin D, Antebi YE, Seger R, Reisner Y. Deletion of al-
loreactive T cells by veto cytotoxic T lymphocytes is mediated through extracellular
signal-regulated kinase phosphorylation. Transplantation 2010;90:380-6.

120